Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
51.69 USD | +1.00% | -1.30% | -17.71% |
Apr. 24 | Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating | MT |
Apr. 23 | Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call |
Evolution of the average Target Price on Incyte Corporation
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Incyte Corporation
Oppenheimer | |
BMO Capital | |
Jefferies & Co. | |
Citigroup | |
JMP Securities | |
Truist Securities | |
Stifel Nicolaus | |
RBC Capital Markets | |
Mizuho Securities | |
SVB Securities LLC | |
Guggenheim | |
Goldman Sachs | |
Morgan Stanley | |
BofA Securities | |
Morningstar | |
TD Cowen | |
Cowen | |
Evercore ISI | |
Piper Sandler | |
Wells Fargo Securities | |
JPMorgan Chase | |
SVB Leerink | |
Benchmark Capital | |
Credit Suisse |
EPS Revisions
- Stock Market
- Equities
- INCY Stock
- Consensus Incyte Corporation